EPO squeezes hESC patenting in line with EU court ruling, but impact could be limited
This article was originally published in SRA
The European Patent Office has declared that a stem cell invention derived using a method that necessarily involves the destruction of a human embryo cannot be patented1,2. In doing so, it has followed last year's ruling from the Court of Justice of the EU, even though as a non-EU body it was not bound to do so.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.